Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

Eli Lilly · Phase 1 · Recruiting · Enrollment 104

NCT07793019

ArmPopulationDoseWeeksEstimandWeight change
Investigational Drug: IBI3042 (Part A)Obesity or overweightn/rn/rn/rn/r
Investigational Drug: IBI3042 (Part B)Obesity or overweightn/rn/rn/rn/r
Matching Placebo (Part B)Obesity or overweightn/rn/rn/rn/r
Orforglipron (Part B)Obesity or overweightn/rn/rn/rn/r
Matching Placebo (Part A)Obesity or overweightn/rn/rn/rn/r